UNSPSC 51431502: Aliskiren

This classification denotes an antihypertensive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 502FWN4Q32. European Medicines Agency schedules Aliskiren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21380. Aliskiren generally arises in the molecular formula C30H53N3O6. The term ALISKIREN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 1, 2001, list 45.) Most nations schedule aliskiren under HS 29242995 and SITC 51479.

As of Q4 2014, ALISKIREN remains the US FDA Preferred Term for this commodity. Aliskiren bears US NLM identifiers UMLS ID C0915224 and NCI Concept Code C65222. SMILES: OC(C(N)CC(C(C)C)Cc1cc(OCCCOC)c(OC)cc1)CC(C(C)C)C(=O)NCC(C)(C)C(=O)N.

UNSPSC 51431502 Aliskiren is a Commodity code covering individual pharmaceutical active ingredients and formulations supplied to state and local health care, emergency response, and public health programs. State and local governments procuring under this code buy specific medications for use by fire rescue services, public health agencies, and state employee health benefit programs. The work entails supplying manufactured pharmaceuticals in quantities ranging from hundreds to thousands of units, meeting strict expiration-date and shelf-life requirements, and complying with FDA manufacturing standards, OSHA hazard communication, and drug supply chain security regulations. Issuing bodies include municipal fire departments, state health and human services agencies, and multistate cooperative purchasing alliances administering contracts on behalf of multiple state and local members.

Recent activity spans Florida, Minnesota, and Texas. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, and Diltiazem formulations) to supply Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with response due April 3, 2026; this exploratory procurement precedes formal solicitation. The Tampa and MMCAP opportunities reflect active, near-term procurement demand; the Texas RFI signals emerging state-level interest in direct manufacturer relationships as an alternative to traditional pharmacy benefit management channels.